PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis

Inclusion Criteria: * Age ≥18 years old * Symptomatic patient according to Rutherford Class 1, 2, 3, 4 or 5 * Clinical degradation by at least 1 Rutherford stage or absence of healing of all skin lesions * Symptoms related to SFA ISR defined by PSVR \> 2.4 within 3 to 24 months after SFA stenting of de novo atherosclerotic lesions. Each patient may have either one or both limbs treated in the study * The target ISR lesion is fully comprised between the origin of the SFA and distally the femoropopliteal crossover (crossing by SFA of medial rim of femur in the PA projection) * Adequate SFA inflow and outflow either pre-existing or successfully re-established (outflow defined as patency of at least one infragenicular artery) * The target lesion must no extend beyond the stent margin * Successful crossing of the target lesion, inflow and outflow lesions with a guidewire * Patient belongs to the French health care system * Written informed consent Exclusion Criteria: * No atheromatous disease * Asymptomatic lesion * Known allergies to heparin, aspirin, other anti-coagulant/antiplatelet therapies, and/or paclitaxel * Acute limb ischemia * Patient on oral anticoagulation therapy * Target lesion requires / has been pre-treated with alternative therapy such as: DES, laser, atherectomy, cryoplasty, cutting/scoring balloon, etc. * Life expectancy \< 1 year * Patient involved in another trial * Refusing patient * Pregnancy